MEIRAGTX HOLDINGS PLC
MGTXNASDAQTrading Snapshot
- Day Range
- $9.58 – $9.93
- 52-Week Range
- $6.62 – $15.35
- Volume (shares)
- 61,650.439
- Avg Volume (shares)
- —
- Shares Outstanding
- 96.0M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- $81M
- Last Q Revenue
- $321M
- P/E Ratio
- 11.4
- P/S Ratio
- 2.3x
- EPS (TTM)
- $0.71
- Dividend Yield
- —
- Dilution (1yr)
- +16.2%
MEIRAGTX HOLDINGS PLC
MGTX
StockOtter · stockotter.spaceAbout MEIRAGTX HOLDINGS PLC
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting
Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms Multiple Posters Highlight the Breadth of Company's Novel Genetic Medicine and Cell Therapy Platforms
Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR)
MeiraGTx (NASDAQ: MGTX - Get Free Report) and aTyr Pharma (NASDAQ: ATYR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strengt
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its
Head-To-Head Analysis: Ascendis Pharma A/S (NASDAQ:ASND) versus MeiraGTx (NASDAQ:MGTX)
Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) and MeiraGTx (NASDAQ: MGTX - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the streng
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in S
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
GV101, a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed a